Newsroom
News & Media
Mar2021
11
Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering
Mar2021
04
Prometheus Biosciences Announces Appointment of Mark Stenhouse as Chief Operating Officer
Mar2021
03
Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023
Feb2021
16
Prometheus Biosciences Announces Appointments of Judith L. Swain, MD and Helen C. Adams, CPA to its Board of Directors
Dec2020
15
Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study
Nov2020
09
Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease
Sep2020
29
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
Aug2020
25
Prometheus Biosciences Appoints Joseph C. Papa to its Board of Directors
Aug2020
13
Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody
Aug2020
04
Prometheus Biosciences Appoints Keith W. Marshall as Chief Financial Officer
Dec2019
10
Prometheus Biosciences Appoints Dr. Thierry Dervieux as Chief Development Officer
Oct2019
03